TherCea Pharma Awarded Competitive Grant from the U.S. National Science Foundation

TheraCea Pharma has been awarded a U.S. National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $275,000 to conduct research and development (R&D) work on developing new diagnostic tools for fast and conclusive assessment of therapy in cancer patients and potentially neurological disorders.

TheraCea team is leveraging foundational scientific research to develop a new class of diagnostic agents aimed at early detection of treatment efficacy in cancer patients. This innovative approach enables patients and healthcare providers to assess the success of cancer therapies within weeks, rather than the months typically required, potentially enhancing patient outcomes and improving treatment decision-making. Ultimately, this advancement stands to benefit society by reducing uncertainty for patients and facilitating more timely and better informed healthcare responses.

TherCea Pharma is the winning startup team for the UACI Sponsored Launch Fueled by Spencer Fane LLP competition

TheraCea Pharma wins the UACI Sponsored Launch Fueled by Spencer Fane LLP competition. We will continue to receive support in the UACI incubation program including resources, facilities, services and expert guidance to grow its business.  

TheraCea was selected from the pool of applicants for its drive in pursuing an innovative solution that addresses a real-world challenge. TheraCea is unleashing the power of precision medicine by developing clinical diagnostic tools for faster and more accurate detection of cancer and neurological disorders, as well as for best-in-class therapy matching and rapid assessment of therapy efficacy. 

The selection was based on TheraCea’s dedication to commercializing its innovation and pursuing a scalable business model. TheraCea has partnered with the National Science Foundation and the National Institutes of Health to move its technology from the chemistry bench to clinics. With more business support, the team has an even greater ability to make a difference both locally and globally. 

TheraCea Receives Additional Funding from Arizona Commerce Authority

TheraCea stands as an active participant in the transformative Back-to-Work Small Business Hiring and Retention Program. This program, meticulously crafted to bolster the growth of small, community-rooted enterprises, holds a key role in our operational strategy. By aligning with this initiative, we are empowered to effectively recruit and maintain a talented workforce, further solidifying our commitment to both our business growth and the local economy. With the program offering financial support of up to $10,000, encompassing hiring and signing bonuses, relocation incentives for new employees, and bonuses aimed at retaining our valuable team, TheraCea is poised to thrive in the dynamic landscape of modern business.

UArizona bioscience startup selected for Flinn Foundation program

TheraCea obtains recognition from Flinn Foundation.

“Tucson-based TheraCea Pharma addresses the greatest challenge in the emerging $145 billion cancer immunotherapy market by providing clinical diagnostic products for patient selection and therapy guidance. TheraCea detects immunotherapy biomarkers using PET imaging. The company has developed a set of diagnostic agents that allow oncologists and pharmaceutical companies to select the right segment of patients who will be responsive to specific immunotherapy drugs.” - Flinn Foundation

TheraCea Awarded Through NIH's TABA Assessment

We are thrilled to announce that our pioneering efforts in the field of radiopharmaceutical kits for immunotherapy have been recognized with the prestigious NIH TABA (Technology Assessment for Biomedical Applications) award. This accolade underscores our commitment to advancing medical science and underscores our dedication to developing cutting-edge solutions that enhance immunotherapy outcomes. The NIH TABA assessment award serves as a testament to our team's unwavering dedication, innovation, and impact in revolutionizing radiopharmaceutical research and its application in the realm of immunotherapy. We remain steadfast in our mission to shape the future of healthcare through groundbreaking advancements.